Black Diamond Therapeutics (BDTX) Director Samarth Kulkarni Receives Award

What Happened Samarth Kulkarni, a director of Black Diamond Therapeutics (BDTX), received a derivative award for 40,000 shares on 2026-06-26. The reported acquisition price is $0.00 (no immediate cash paid); the award is a derivative grant (an option/award), not an open-market purchase or sale.

Key Details

• Transaction date: 2026-06-26; Form 4 filed: 2026-06-29 (Period of Report: 2026-06-26).
• Reported terms: 40,000 shares acquired as a derivative award at $0.00.
• Shares owned after transaction: not specified in the provided filing.
• Footnote (vesting): the option/shares vest and become exercisable in full upon the earlier of (i) June 26, 2027 or (ii) the issuer’s next annual meeting of stockholders, subject to continued service.
• No indication in this filing of a 10b5-1 plan, tax withholding, or immediate sale.

Context This is a compensation-related derivative grant to a director and should be read as a standard equity award subject to vesting, not an immediate purchase or sale of stock. The filing does not specify exercise price or post-vesting actions; it simply reports the grant and its vesting schedule.